Induction of leukemia-specific antibodies by immunotherapy with leukemia-cell-derived heat shock protein 70

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1427-1434

  Jimbo, Junko ^a   Sato, Kazuya ^a   Hosoki, Takaaki ^a   Shindo, Motohiro ^a   Ikuta, Katsuya ^a   Torimoto, Yoshihiro ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CANCER ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; HEAT SHOCK PROTEIN 70; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; TH2 CELL;

ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HSP70 HEAT-SHOCK PROTEINS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-4; LEUKEMIA; MICE; MICE, INBRED BALB C;

EID: 44449140618     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00829.x     Document Type: Article

References (45)

1. Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today 1998; 4: 478-84.
2. Nieland TJF, Tan MCA, Monne-van Muijien M, Koning F, Kruisbeek AM, Van Bleek GM. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein gp96/grp94. Proc Natl Acad Sci USA 1996; 93: 6135-9.
3. Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003; 362: 469-76.
4. Srivastava PK, Udono H, Blachere N, Li Z. Heat shock proteins transfer peptide during antigen processing and CTL priming. Immunogenetics 1994; 39: 93-8.
5. Srivastava PK. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002; 2: 185-94.
6. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: Repercussions in cancer therapy. J Leukoc Biol 2007; 81: 15-27.
7. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 1998; 8: 657-65.
8. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278: 117-20.
9. Srivastava PK. Therapeutic cancer vaccines. Curr Opin Immunol 2006; 18: 201-5.
10. Aalamian M, Fuchs E, Gupta R, Levey DL. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Urol Oncol 2006; 24: 425-33.
11. Pilla L, Patuzzo R, Rivoltini L et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006; 55: 958-68.
12. Li Z, Qiao Y, Liu B et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 4460-8.
13. Linker CA. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003; 31: 731-8.
14. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
15. Brunvand MW, Bensinger WI, Soll E et al. High-dose fractionated total body-irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous bone marrow transplantation and peripheral blood stem cells. Bone Marrow Transplant 1996; 18: 131-41.
16. Sato K, Torimoto Y, Tamura Y et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood 2001; 98: 1852-7.
17. Iuchi Y, Torimoto Y, Sato K et al. Combined use of dendritic cells enhances specific antileukemia immunity by leukemia cell-derived heat shock protein 70 in a mouse model with minimal residual leukemia cells. Int J Hematol 2006; 84: 449-58.
18. Mine T, Gouhara R, Hida N et al. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003; 94: 548-56.
19. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002; 99: 1517-26.
20. Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001; 7: 3950-62.
21. Kim KJ, Langevin CK, Merwin RM, Sachs DH, Asfsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979; 122: 549-54.
22. Chesebro B, Wehrly K, Chesebro K, Portis J. Characterization of Ia8 antigen, Thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol 1976; 117: 1267-74.
23. Cikes M, Friberg S Jr, Klein G. Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst 1973; 50: 347-62.
24. Armstrong AC, Dermime S, Allinson CG et al. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: Induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J Immunol 2002; 168: 3983-91.
25. Mezianeel K, Bhattacharyya T, Armstrong AC et al. Use of adenoviruses encoding CD40 L or IL-2 against B cell lymphoma. Int J Cancer 2004; 111: 910-20.
26. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993; 178: 1391-6.
27. Gomes B, Savignac M, Cabral MD et al. The cGMP/protein kinase G pathway contributes to dihydropyridine-sensitive calcium response and cytokine production in TH2 lymphocytes. J Biol Chem 2006; 281: 12421-7.
28. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004; 83: 634-45.
29. Zhu X, Zhao X, Burkholder WF et al. Structural analysis of substrate binding by the molecular chaperone DnaK. Science 1996; 272: 1606-14.
30. Ishii T, Udono H, Yamano T et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999; 162: 1303-9.
31. + T cells in IL-4 knockout mice. Eur J Immunol 1999; 29: 1397-405.
32. Bennett AM, Elvin SJ, Wright AJ, Jones SM, Phillpotts RJ. An immunological profile of BALB/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 2000; 19: 337-47.
33. Ma JH, Sui YF, Ye J et al. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 2005; 54: 907-14.
34. Manjili MH, Wang XY, Chen X et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003; 171: 4054-61.
35. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 1997; 57: 728-34.
36. Schelbusch H, Wabner U, Grunn U, Schultes B. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 1995; 14: 167-74.
37. Suzuki K, Sahara H, Okada Y et al. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. J Immunol 1999; 163: 2783-91.
38. Castelli C, Ciupitu AM, Rini F et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001; 61: 222-7.
39. Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Curr Opin Invest Drugs 2001; 2: 133-5.
40. Mine T, Sato Y, Noguchi M et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004 (Feb 1); 10 (3): 929-37.
41. + T cells reactive to a class I tumor peptide. J Immunol 2004 (Feb 15); 172 (4): 2659-67.
42. Qian J, Wang S, Yang J et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: Generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res 2005; 11: 8808-15.
43. + mice. Cancer Sci 2007; 98: 1930-5.
44. Dillman RO. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol 2003; 30: 434-47.
45. Cartron G, Watier H, Golay J, Solal-Celibny P. From the bench to the bedside: Ways to improve rituximab efficacy. Blood 2004; 104: 2635-42.